NCT02993237View on ClinicalTrials.gov

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 23, 2017

Primary Completion Date

May 25, 2017

Study Completion Date

May 25, 2017

Conditions

HIV-1

Interventions

DRUG

DRV/COBI FDC placebo tablet

Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC

DRUG

D/C/F/TAF FDC placebo tablets

Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.

Trial Locations (4)

30350

Emory University, Atlanta

38105

St Jude Children's Research Hospital, Memphis

77030

University of Texas Health Science Center, Houston

85016

Phoenix Children's Hospital, Phoenix

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02993237 - Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets | Biotech Hunter | Biotech Hunter